title: Regulation of postprandial blood metabolic variables by TEMPO-oxidized cellulose nanofibers.
abstract: Wood cellulose was converted to individual nanofibers of approximately 4 nm width and 380-570 nm average length by TEMPO-mediated oxidation. The TEMPO-oxidized cellulose nanofibers (TOCNs) were orally administered with glucose and glyceryl trioleate to mice and postprandial responses of blood glucose, insulin, glucose-dependent insulinotropic polypeptide (GIP), and triglycerides were studied. Both blood insulin and GIP concentrations were decreased by TOCN with a carboxyl content and aspect ratio of 1.2 mmol g(-1) and 120, respectively, in dose-dependent manners (0-0.3 mg g(-1) body weight). Of the TOCNs examined, that with a carboxyl content and aspect ratio of 1.2 mmol g(-1) and 120, respectively, was the most effective in reducing postprandial blood glucose, plasma insulin, GIP, and triglyceride concentrations. Thus, TOCNs were found to exhibit characteristic biological activities when administered to mice and may have potential applications in biomedical fields for human health.
authors: Global R&D-Biological Science, Kao Corporation, 2606 Akabane, Ichikai-machi, Haga-gun, Tochigi 321-3497, Japan. shimotoyodome.akira@kao.co.jp
authors: Akira
authors: A
authors: Shimotoyodome
authors: Junko
authors: J
authors: Suzuki
authors: Yoshiaki
authors: Y
authors: Kumamoto
authors: Tadashi
authors: T
authors: Hase
authors: Akira
authors: A
authors: Isogai
mesh_terms: D000818:Animals; D040761:Biomimetic Materials / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002483:Cellulose, Oxidized / Q000737:chemistry* / Q000378:metabolism; D003497:Cyclic N-Oxides / Q000737:chemistry*; D004043:Dietary Fiber / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005995:Glyceryl Ethers / Q000008:administration & dosage; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000503:physiopathology; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D057139:Nanofibers / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D010084:Oxidation-Reduction; D019518:Postprandial Period / Q000187:drug effects; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D002483:Cellulose, Oxidized; D003497:Cyclic N-Oxides; D004043:Dietary Fiber; D005995:Glyceryl Ethers; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin; D014280:Triglycerides; C035206:glyceryl trioleyl ether; D005749:Gastric Inhibitory Polypeptide; C003959:TEMPO